The Cost of Inhalers Is Going Down

Great news! The cost of asthma inhalers is trending down. That’s because three major manufacturers announced they will cap out-of-pocket costs for their asthma inhaler products at $35 a month. 

The changes begin on June 1 for some medicines. The price caps apply to people who have commercial insurance or no insurance.   

Breathe Easier: Cleaner Air on the Way

The Environmental Protection Agency (EPA) issued new rules for car and light truck emissions starting in the 2027 model year.  

Transportation-related emissions are the largest contributor to the greenhouse gases driving climate change.  

Our voice is stronger with you

RESEARCH NEWS

Our March 2024 research update includes summaries on current clinical trials, surveys, and study outcomes on the following topics: 

Anaphylaxis 

• Epinephrine nasal spray and sublingual (under-the-tongue) film 

Asthma 

• New research on DUPIXENT® for adults with uncontrolled moderate-to-severe asthma 

Chronic Obstructive Pulmonary Disease (COPD) 

• FDA priority review of DUPIXENT® for treatment of COPD with type 2 inflammation 

• New clinical trials for people with COPD 

COVID-19 

• COVID-19 vaccination during pregnancy protects infants for 6 months 

Chronic Spontaneous Urticaria (CSU) 

• Results from a clinical study on Rilzabrutinib  

To read this month’s asthma and allergy research news, visit our blog. 

CLINICAL TRIALS

Are You Currently Taking Oral Corticosteroids (OCS) for Your Asthma?

Would you like to contribute to important new research? SUNRISE is a clinical study investigating whether a new biologic treatment called tezepelumab may help to reduce or remove the need for OCS in adults with severe asthma. The study is looking for people who:

• Are between 18 and 80 years of age
• Have had an asthma diagnosis for at least 1 year
• Have been taking OCS for asthma for at least 6 months
• Have been using inhaled corticosteroids for at least a year, and a long-acting beta 2-agonist (LABA) for at least 3 months
• Have not been receiving any biologic treatment for asthma for at least 4 months

Sponsored by AstraZeneca
 

LEARN MORE

SURVEYS

Asthma or Chronic Rhinosinusitis with Nasal Polyps Survey 

CME OPPORTUNITIES

If you are a health care professional, earn AMA PRA Category 1 Credit™ by watching our continuing medical education (CME) programs on asthma and atopic dermatitis, available on demand.  

Applying Guidelines and Latest Evidence to the Management of Moderate-to-Severe Asthma in Children and Adults 

Webinar topics: 

• Patient cases showing the management of asthma with comorbidities 

• The impact of uncontrolled moderate-to-severe asthma on lung development in children 

• Strategies to develop personalized asthma treatment plans 

                                    
                                      WATCH ON DEMAND

Atopic Dermatitis and Its Comorbid Conditions: How Knowing About Them Will Help Guide Your Treatment Decisions 

Webinar topics: 

• Treatments for moderate-to-severe atopic dermatitis 

• How the presence of comorbidities can influence treatment 

• How to help patients reach long-term control of their disease 

                                   
                                       WATCH ON DEMAND 

Did You Miss Our Previous Issue?

Check out our most recent issue for news on the most challenging places to live with seasonal allergies, the importance of community in asthma management, and more! 

                                   READ THE LATEST ISSUE

Thank you for your continued support.
Visit aafa.org and kidswithfoodallergies.org